People with dementia: what is known about their experience of cancer treatment and cancer treatment outcomes? A systematic review

Hopkinson, Jane B.; Milton, Rebecca; King, Amanda; Edwards, Deborah

doi:10.1002/pon.4185

Cited by 45 publications

(62 citation statements)

References 23 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In demented patients, the diagnosis of cancer is frequently delayed compared to those without dementia. This in turn is associated with higher treatment‐related complication rates and a more unfavorable prognosis in terms of survival .…”

Section: Psycho‐oncological Aspectsmentioning

confidence: 99%

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

Becker

Eigentler

Frerich

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Merkel cell carcinoma (MCC, ICD‐O M8247 / 3) is a rare malignant primary skin tumor with epithelial and neuroendocrine differentiation. The neoplastic cells share many morphological, immunohistochemical and ultrastructural characteristics with Merkel cells of the skin. The diagnosis of MCC is rarely made on clinical grounds. Histological and immunohistochemical studies are usually required to confirm the clinical suspicion. Given the frequent occurrence of occult lymph node metastasis, sentinel lymph node biopsy should be performed once distant metastasis has been ruled out by cross‐sectional imaging. Primary tumors without evidence of organ metastases are treated with complete surgical excision with appropriate surgical margins. Radiation therapy should be considered at all stages of the disease. For advanced MCC that is no longer amenable to curative treatment by surgery or radiation therapy, there is currently no established systemic therapy for which an improvement in recurrence‐free survival or overall survival has been demonstrated in a prospective randomized trial. However, immunotherapy using PD‐1/PD‐L1 blockade seems to be superior to chemotherapy. Various factors warrant that further diagnostic and therapeutic interventions be determined by an interdisciplinary tumor board. These factors include the tumor's aggressiveness, the frequent indication for sentinel lymph node biopsy along with the frequent occurrence in the head and neck region, the potential indication for adjuvant radiation therapy as well as the complexity of the required diagnostic workup.

show abstract

Section: Psycho‐oncological Aspectsmentioning

confidence: 99%

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

Becker

Eigentler

Frerich

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Previous reviews have struggled to identify many studies that have directly explored the experiences of people with dementia and their caregivers in this context . A recent review by Hopkinson and colleagues, which sought to find out about the experiences of people with cancer and dementia, found that people with dementia were more likely to have a delayed diagnosis and receive fewer treatments compared with cancer patient who did not have dementia …”

Section: Introductionmentioning

confidence: 99%

“…16 A recent review by Hopkinson and colleagues, which sought to find out about the experiences of people with cancer and dementia, found that people with dementia were more likely to have a delayed diagnosis and receive fewer treatments compared with cancer patient who did not have dementia. 17 The aim of this review was to address a gap in knowledge by exploring how caregivers are involved in making cancer treatment decisions for older people with dementia who receive a new diagnosis of cancer.…”

mentioning

confidence: 99%

How are caregivers involved in treatment decision making for older people with dementia and a new diagnosis of cancer?

Martin¹,

Shrestha²,

Burton

et al. 2019

Psycho-Oncology

View full text Add to dashboard Cite

Objective To explore how caregivers are involved in making treatment decisions for older people living with dementia and a new diagnosis of cancer. Method A systematic review of PubMed, CINAHL, PsycINFO, Web of Science, and Scopus databases was conducted. Studies recruiting formal or informal caregivers for older people with dementia and a diagnosis of cancer were considered for inclusion. Results Of 1761 articles screened, 36 full texts were assessed for eligibility, and six were included in the review. This review has identified that health care professionals (HCPs) are often unaware of the coexistence or severity of dementia in cancer patients, and therefore fail to properly address care needs as a result. While caregivers are relied on to help make decisions, they have unmet information needs and feel excluded from decision‐making. Conclusion Treatment decision making in the context of older adults with dementia and a new diagnosis of cancer needs further research. This will help HCPs to understand their needs and improve the experience of decision making for both caregivers and the people that they care for.

show abstract

“…Die Diagnose der Tumorerkrankung wird bei Patienten, die an Demenz leiden, oft später gestellt als bei Patienten ohne Demenz. Dies ist wiederum mit einer erhöhten Komplikationsrate in Bezug auf die Therapie und eine schlechtere Prognose in Bezug auf das Überleben vergesellschaftet .…”

Section: Psychoonkologische Aspekteunclassified

S2k‐Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018

Becker

Eigentler

Frerich

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Das Merkelzellkarzinom (MCC, ICD‐O M8247/3) ist ein seltener, maligner, primärer Hauttumor mit epithelialer und neuroendokriner Differenzierung. Die Tumorzellen teilen viele morphologische, immunhistochemische und ultrastrukturelle Eigenschaften mit den Merkelzellen der Haut. Die Diagnose MCC wird selten klinisch gestellt. Erst histologisch und immunhistochemisch wird der Verdacht auf ein MCC bestätigt. Nachdem eine Fernmetastasierung durch Bildgebung mit Schnittbildverfahren ausgeschlossen worden ist, sollte aufgrund der hohen Zahl von okkulten Lymphknotenmetastasen eine Schildwächterlymphknotenbiopsie erfolgen. Bei Primärtumoren ohne Hinweise auf das Vorliegen von Organmetastasen soll eine vollständige chirurgische Exzision mit Sicherheitsabstand erfolgen. Die strahlentherapeutische Behandlung sollte in allen Stadien der Tumorerkrankung in Betracht gezogen werden. Für das fortgeschrittene, operative oder strahlentherapeutische nicht mehr kurativ behandelbare MCC gibt es bisher keine etablierte systemische Therapie, für die in einer prospektiv‐randomisierten Studie eine Verbesserung des rezidivfreien Überlebens oder des Gesamtüberlebens demonstriert werden konnte. Eine Immuntherapie mittels PD‐1/PD‐L1‐Blockade erscheint aber einer Chemotherapie überlegen zu sein. Aufgrund seiner Aggressivität, der in der Regel gegebenen Indikation zur Schildwächterlymphknotenbiopsie bei gleichzeitig häufiger Lokalisation im Kopf‐Hals‐Bereich, der zu evaluierenden Indikation einer adjuvanten Radiotherapie sowie der Komplexität der notwendigen Diagnostik zur korrekten Prognoseabschätzung soll das Vorgehen im Rahmen einer interdisziplinären Zusammenarbeit (interdisziplinäres Tumorboard) festgelegt werden.

show abstract

People with dementia: what is known about their experience of cancer treatment and cancer treatment outcomes? A systematic review

Cited by 45 publications

References 23 publications

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

How are caregivers involved in treatment decision making for older people with dementia and a new diagnosis of cancer?

S2k‐Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018

Contact Info

Product

Resources

About